<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109383">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059564</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EXC-102</org_study_id>
    <nct_id>NCT02059564</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label
      Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator
      on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective

      - effect of multiple different weekly and monthly doses of HM11260C and liraglutide
      (Victoza) as active control on gastric emptying

      Secondary Objectives

        -  evaluate the pharmacodynamic (PD) effects of multiple weekly and monthly doses of
           HM11260C and liraglutide after a Mixed Meal Tolerance Test

        -  evaluate the islet β-cell function after a graded glucose infusion (GGI) of different
           doses of HM11260C and liraglutide

        -  evaluate safety and tolerability of different doses of HM11260C and liraglutide

        -  evaluate the pharmacokinetic (PK) effect of multiple weekly and monthly doses of
           HM11260C
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PK profile of acetaminophen</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, AUC at 13 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting plasma glucose (FPG), Postprandial glucose (PPG), Insulin, C-peptide, HbA1c at 13 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence and severity of adverse events, findings on physical examination, clinical laboratory abnormalities at 18 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The weekly treatment of the 6 mg HM11260C or placebo will be maintained</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM11260C</intervention_name>
    <description>doses of 6 mg, 16 mg</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>LAPS-Exendin-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>Normal saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Victoza</intervention_name>
    <description>doses of 1.8 mg</description>
    <arm_group_label>Cohort C</arm_group_label>
    <other_name>Liraglutide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 to ≤ 70 years of age at the time of the Screening Visit

          -  History of type 2 diabetes

          -  Body mass index (BMI) ≥18 to ≤45 kg/m2 at the Screening Visit

          -  Use of approved methods of contraception

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Significant acute diabetic proliferative retinopathy or severe neuropathy

          -  Systolic blood pressure &gt;160 mm Hg and/or diastolic blood pressure &gt;100 mm Hg at
             screening

          -  Pregnant or lactating women

          -  Participation in an investigational study within 30 days prior to randomization

          -  History of any major surgery within 6 months prior to Screening

          -  History of any serious adverse reaction or hypersensitivity to any of the product
             components.

          -  History of renal disease or significantly abnormal kidney function tests at Screening

          -  History of hepatic disease or significantly abnormal liver function tests

          -  History of any active infection within 30 days prior to Randomization

          -  Presence of clinically significant physical, laboratory, or ECG findings at Screening
             that, in the opinion of the Investigator, may interfere with any aspect of study
             conduct or interpretation of results

          -  Concurrent conditions that could interfere with safety and/or tolerability
             measurements per the investigator

          -  Donation or loss of &gt;500 mL of blood or blood product within 56 days of Randomization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanmi Clinical</last_name>
    <role>Principal Investigator</role>
    <affiliation>California, United States</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanmi Clinical</last_name>
    <email>clinical4@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanmi</name>
      <address>
        <city>California</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanmi Clinical</last_name>
      <email>clinical4@hanmi.co.kr</email>
    </contact>
    <investigator>
      <last_name>Hanmi Clinical</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Exendin-4</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
